Skip to main content
. 2023 Apr 23;19(7):2270–2288. doi: 10.7150/ijbs.81415

Figure 1.

Figure 1

Flubendazole blocks tumor proliferation of HCC in vitro and in vivo. (A) Cell viabilities of Huh7, MHCC-97H and SNU449 cells treated with 10 µM FDA approved drugs for 24, 48, 72 hours. (B), (C) The upper parts show the subcutaneous tumor volumes of Huh7 (n = 6) and MHCC-97H (n = 8) in nude mice treated with control (DMSO) or flubendazole (40 mg/kg) by peritoneal injection. The lower parts show the tumor images and weights of nude mice treated with control (DMSO) or flubendazole. Scale bars, 1 cm. (D) Chemical structure of flubendazole. (E) Colony formation assays of HCC cells treated with 0.25, 0.50, 1.00 µM flubendazole for 72 hours. (F) Cell viabilities and IC50 of HCC cells treated with different concentrations of flubendazole for 72 hours. (G) and (H) Representative images and quantification of HCC cells treated with control, 0.25 or 0.5 µM flubendazole for 72 hours. Cells were then stained with PI and DNA content was quantified. Data are presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. The P values were calculated by two-way analysis of ANOVA for tumor volumes, unpaired Student's t test for tumor weights in B and C and unpaired Student's t test in G.